• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » A Novel Treatment for Methamphetamine Use Disorder
RESEARCH UPDATE

A Novel Treatment for Methamphetamine Use Disorder

January 31, 2022
David A. Moltz, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
David A. Moltz, MD. Dr. Moltz has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
REVIEW OF: Trivedi MH et al, N Engl J Med 2021;384(2):140–153

STUDY TYPE: Randomized, double-blind, placebo-controlled trial with sequential parallel comparison design

Methamphetamine use disorder is an increasing cause of overdose deaths in the US. Pharmacologic options are scarce, but pilot studies suggest that bupropion and naltrexone may be effective, either alone or in combination. This study tested them in combination.

The authors designed this double-blind, randomized, placebo-controlled study in two phases. First, patients were randomized to treatment or placebo for six weeks, with three times as many assigned to placebo. In the second stage, patients who responded to placebo were removed, and the remaining placebo non-responders were re-randomized to either more placebo or active treatment for another six weeks, this time with equal numbers in the placebo and treatment arms. The point of this design was to dampen the placebo response in the second phase of the study.

The subjects, recruited through advertisements and direct referrals, were adults with moderate to severe methamphetamine use disorder who wanted to quit or reduce use. On average, they had used methamphetamine on 27 of the previous 30 days. The active combo treatment was extended-release (ER) naltrexone 380 mg IM every three weeks and ER bupropion 450 mg daily.

There were 403 participants in stage 1, and 225 who did not respond to placebo were re-randomized to stage 2. Overall retention was good (77.4%). The primary outcome was response, defined as three out of four urine tests negative for methamphetamine in the last two weeks of stage 1 or stage 2.

In terms of results, naltrexone-bupropion was significantly more effective than placebo. The weighted average response was 13.6% for the active group and 2.5% for placebo (p < 0.001), and the number needed to treat (NNT) was 9. Serious adverse events, such as nausea, vomiting, and constipation, were evenly divided between active and placebo conditions.

TCPR’S TAKE
Naltrexone-bupropion combination is somewhat effective for methamphetamine use disorder. While the NNT of 9 is on the small side, this treatment was backed by a well-designed trial, and in a disorder with such devastating consequences, every tool is important.
General Psychiatry
KEYWORDS bipolar-depression bipolar-ii bipolar_disorder lumateperone second-generation-antipsychotics-sgas
David A. Moltz, MD.

A Psychosocial Intervention for Chronic Pain and SUD

More from this author
www.thecarlatreport.com
Issue Date: February 1, 2022
SUBSCRIBE NOW
Table Of Contents
An Off-Label Guide to Gabapentin
MDMA-Assisted Therapy for Severe PTSD
Lumateperone in Bipolar Depression
A Novel Treatment for Methamphetamine Use Disorder
Lybalvi: The Diet Olanzapine
Raising the Bar in Schizophrenia Treatment
CME Post-Test - Schizophrenia, TCPR, February 2022
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.